CB 399: Ludwig/Landry Nanocourse: Resistance to Cancer Therapies Spring 2016

Ludwig/Landry Nanocourse: Resistance to Cancer Therapies

Course Co-Directors: Joan Brugge PhD, George Demetri MD and Stephen Hodi MD

Curriculum Fellows: Megan Mittelstadt PhD

Course Faculty: Catherine Dubreuil PhD, Catherine_Dubreuil@hms.harvard.edu

 **NOTE, ppt slides posted below - must log in to view.**

While significant advances have been made in the treatment of cancer, both primary and acquired resistance to anticancer therapeutics remain significant barriers that limit our ability to cure disease.  This nanocourse will provide an overview of basic and clinical mechanisms of cancer resistance, including the complexity and plasticity of tumor cells and the microenvironment, heterogeneity within and across tumors, as well as the emerging breakthroughs and challenges in immune-oncology.  Rational combinations to overcome resistance will also be discussed in detail, and students will work in groups to develop practical concepts to test and overcome resistance in cancer.

This nanocourse is sponsored by the Landry Cancer Biology Consortium and the Ludwig Consortium.

Schedule: 
First Session (open to the Harvard community): Monday, May 2, 2016 9am-12pm

Location: Goldenson 122

Second Session (limited to registered students): Tuesday, May 24, 9am-12pm

Location: TMEC 447

 

DROP DEADLINE: Monday, April 25, 2016

 Assignment:

Written Assignment due by 9am, Friday, May 20th 2016 to Catherine_Dubreuil@hms.harvard.edu

Students will work together in groups (2-3 students per group, 6 groups max) to complete a written mini-proposal, one document submitted per group. Your proposal should be for a provocative approach to overcoming therapeutic resistance in any disease indication with a clearly defined patient population. Any therapeutic strategy/approach related to therapeutic resistance in cancer is acceptable. Course faculty will be available following the first session to answer any questions you have regarding your written proposals.

Written proposals should be no longer than two pages single-spaced (not including references – if information can be contained in one page, that is preferable) and include:

1) Concept Title

2) Background and Definition of the idea/concept

3) Concept and Scientific Rationale

And should briefly address:

- Potential challenges and roadblocks in the development of this therapeutic strategy

- Contributions of each team member

Proposal Pitch (presentations in class on Tuesday, May 24):

During the second session, each student group will pitch their proposal to the course faculty. Each group member should be prepared to answer questions regarding the group’s proposal. Presentations should have no more than 10 slides. Teams will be given 15 minutes of presentation time plus 10-15 minutes of discussion. Groups should begin with a 30 second elevator pitch during their title slide, then move on to give the background and concept – quickly convey your concept and be persuasive.

AUDITORS (Post-Docs, Faculty, or Staff) DO NOT NEED TO SIGN UP TO ATTEND THE 1st SESSION.  PLEASE DO NOT ENROLL.